Neurodegenerative disorders linked to protein dysfunction are difficult to study because of the complexity of the underlying molecular interactions. A great example is TAR DNA-binding protein 43 (TDP-43), found in diseases like amyotrophic lateral sclerosis (ALS), Parkinson's disease and several types of dementia. Today, researchers are still trying to answer how TDP-43's activity translates into broader cellular effects.

In this webinar, we will explore how to combine CRISPR-based screening approaches and pathway-level analysis for biological interpretation that encompasses more than gene-level observations. Using QIAGEN Ingenuity Pathway Analysis (IPA), we will demonstrate strategies to contextualize screening results and assess the functional relevance of candidate modifiers within cellular networks.

You will learn: 

1. About the role of TDP-43 in the cell and its connection to neuropathies
   

2. How to investigate CRISPR screen hits using IPA

3. How to validate the rescue effect of genetic modifiers using pathway activation scores